Back

Scenario 3 - Long-term safety of new anti-diabetic drugs.

26 August 2018 (11:55 - 12:20)
Organised by:
Congress Presentation Part of: Meet the Experts - Safety first: avoiding adverse events with new cardiovascular drugs Cardiovascular Pharmacotherapy ESC Premium Access ESC Congress 2018

About the speaker

Photo
Professor Alexander Niessner

Landstrasse Clinic, Vienna (Austria)

5 More presentations in this session

Presentation thumbnail
Safety first: avoiding adverse events with new cardiovascular drugs - Panel
Presentation thumbnail
Introduction - Safety first: avoiding adverse events with new cardiovascular drugs
Doctor M. Alonso Garcia (London, GB)
Slides Video
Presentation thumbnail
Scenario 1 - Adverse events of new lipid lowering drugs.
Doctor T. Hall (Oslo, NO)
Slides Video
Presentation thumbnail
Scenario 2 - Neprilysin inhibitors in heart failure: safety and adverse events
Assistant Professor M. Kaluzna-Oleksy (Poznan, PL)
Slides
Presentation thumbnail
Safety first: avoiding adverse events with new cardiovascular drugs - Take Home Message.
Professor J. Tamargo (Madrid, ES)
Slides Video

Access the full session

Session thumbnail
Meet the Experts - Safety first: avoiding adverse events with new cardiovascular drugs

The Event

Event poster

ESC Congress 2018

26 August 2018 11:55 CET
You may be interested in
thumbnail
Congress Session
Guidelines in Practice: 2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes
27 August 2023
thumbnail
Congress Presentation
Glucose lowering drugs or strategies, major adverse cardiovascular events and heart failure outcomes, and association with weight loss - meta-analysis of large cardiovascular outcome trials
2 September 2019
thumbnail
Congress Presentation
New insights into optimal duration of DAPT for high-risk "TWILIGHT-like" patients with diabetes mellitus undergoing PCI: a focus on diabetes mellitus as a high-risk patient group
28 August 2021
thumbnail
Congress Presentation
Influence of long-term sodium-glucose cotransporter 2 inhibition on cardiac remodeling in rats with type 1 diabetes mellitus
27 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources